Key Takeaways
- • Osanni Bio closed a $190 million Series B financing round led by Patient Square Capital, a healthcare-focused investment firm, signaling confidence in the company's therapeutics development platform.
- • The round included participation from existing investors the Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund, demonstrating sustained investor backing across multiple institutional stakeholders.
- • Osanni Bio operates as a development-stage therapeutics platform focused on reinventing drug discovery and development processes, positioning itself within the competitive biotech innovation sector.
- • The $190 million raise represents a significant capital infusion for a company at the development stage, reflecting investor appetite for novel approaches to medicine discovery.
Summary
Osanni Bio announced the completion of a $190 million Series B financing round on July 1, 2026, marking a substantial funding milestone for the San Francisco-based development-stage therapeutics company. Patient Square Capital, a leading healthcare investment firm, led the round, with participation from the company's existing investor base including the Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund.
The company positions itself as a platform reinventing the discovery and development processes for new medicines, operating within the broader therapeutics innovation landscape. The financing demonstrates continued institutional confidence in Osanni Bio's approach and technology platform, as evidenced by both the leading investor's fresh commitment and the participation of multiple existing stakeholders.
The $190 million Series B raise reflects strong investor demand for development-stage biotech companies pursuing novel methodologies in drug discovery. The involvement of Patient Square Capital—a firm with established healthcare investment expertise—alongside specialized investors such as the Retinal Degeneration Fund suggests the company may be pursuing applications across multiple therapeutic areas or disease indications. The sustained participation of existing investors indicates successful execution of prior milestones and continued strategic alignment with the company's development roadmap.
The company positions itself as a platform reinventing the discovery and development processes for new medicines, operating within the broader therapeutics innovation landscape. The financing demonstrates continued institutional confidence in Osanni Bio's approach and technology platform, as evidenced by both the leading investor's fresh commitment and the participation of multiple existing stakeholders.
The $190 million Series B raise reflects strong investor demand for development-stage biotech companies pursuing novel methodologies in drug discovery. The involvement of Patient Square Capital—a firm with established healthcare investment expertise—alongside specialized investors such as the Retinal Degeneration Fund suggests the company may be pursuing applications across multiple therapeutic areas or disease indications. The sustained participation of existing investors indicates successful execution of prior milestones and continued strategic alignment with the company's development roadmap.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.